Haftungsausschluss: Diese Website bündelt öffentlich verfügbare Daten aus offiziellen Quellen wie FDA, ClinicalTrials.gov, PubMed und SEC EDGAR nur zur allgemeinen Information. Sie stellt keine medizinische Beratung, Diagnose, Behandlungsempfehlung oder Anlageberatung dar.

Klinische Studie

A Clinical and Imaging Registry of Transcatheter Aortic Valve Implantation Using JenaValve System/ J-Valve System for Patients With Pure Aortic Regurgitation

NCT: NCT07021612 · RECRUITING

NCT-IDNCT07021612
Medizinische Daten: StatusRECRUITING
Startdatum2025-04-01
Abschluss2028-09-30
SponsorPrince of Wales Hospital, Shatin, Hong Kong (OTHER)
First posted
Last updated

Kurzzusammenfassung

Aortic regurgitation (AR) is not uncommon. Transcatheter aortic valve implantation (TAVI) for treating pure aortic regurgitation is a potential future treatment option for pure AR especially in patients having high risk for open heart surgery. TAVI using dedicated device for pure AR has a different anchor mechanism to TAVI for aortic stenosis (AS). AR patientsalso have different cardiac flow pattern, aortic root pathology and left ventricular remodeling pattern compared to AS patients. Subclinical leaflet thrombosis has been described in AS patient receiving TAVI, which will affect the durability and antithrombotic regime. Follow-up imaging for dedicated TAVI device in AR patient is limited.

Offizielle Quelle

Auf ClinicalTrials.gov ansehen →

Daten aus der ClinicalTrials.gov-API. Den aktuellsten Status finden Sie im offiziellen Eintrag.

↑